LOF PARTNERS LLC 4

Accession 0001181431-13-006843

CIK 0000810084other

View on SEC.gov Company Profile

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 4:57 PM ET

Size

19.4 KB

Accession

0001181431-13-006843

Insider Transaction Report

Form 4

Period: 2009-12-18

BIOJECT MEDICAL TECHNOLOGIES INCBJCT

LIFE SCIENCES OPPORTUNITIES FUND II LP

10% Owner

Transactions

Other
Series G Preferred Stock
2009-12-18$13.00/sh+44,323$576,199→ 44,323 total
Exercise: $13.00From: 2009-12-18→ Common Stock (4,432,300 underlying)
Other
Convertible Note
2009-12-18→ 0 total
Exercise: $508896.00From: 2007-12-10Exp: 2009-05-15→ Common Stock (678,538 underlying)
Other
Series G Preferred Stock
2009-12-18$13.00/sh+9,665$125,645→ 9,665 total
Exercise: $13.00From: 2009-12-18→ Common Stock (966,500 underlying)
Other
Convertible Note
2009-12-18→ 0 total
Exercise: $91104.00From: 2007-12-05Exp: 2009-05-15→ Common Stock (121,472 underlying)

GALE JAMES C

Director

Transactions

Other
Series G Preferred Stock
2009-12-18$13.00/sh+9,665$125,645→ 9,665 total
Exercise: $13.00From: 2009-12-18→ Common Stock (966,500 underlying)
Other
Convertible Note
2009-12-18→ 0 total
Exercise: $91104.00From: 2007-12-05Exp: 2009-05-15→ Common Stock (121,472 underlying)
Other
Convertible Note
2009-12-18→ 0 total
Exercise: $508896.00From: 2007-12-10Exp: 2009-05-15→ Common Stock (678,538 underlying)
Other
Series G Preferred Stock
2009-12-18$13.00/sh+44,323$576,199→ 44,323 total
Exercise: $13.00From: 2009-12-18→ Common Stock (4,432,300 underlying)

LIFE SCIENCES OPPORTUNITIES FUND INSTITTUTIONAL II LP

10% Owner

Transactions

Other
Convertible Note
2009-12-18→ 0 total
Exercise: $91104.00From: 2007-12-05Exp: 2009-05-15→ Common Stock (121,472 underlying)
Other
Series G Preferred Stock
2009-12-18$13.00/sh+44,323$576,199→ 44,323 total
Exercise: $13.00From: 2009-12-18→ Common Stock (4,432,300 underlying)
Other
Series G Preferred Stock
2009-12-18$13.00/sh+9,665$125,645→ 9,665 total
Exercise: $13.00From: 2009-12-18→ Common Stock (966,500 underlying)
Other
Convertible Note
2009-12-18→ 0 total
Exercise: $508896.00From: 2007-12-10Exp: 2009-05-15→ Common Stock (678,538 underlying)

LOF PARTNERS LLC

Other

Transactions

Other
Convertible Note
2009-12-18→ 0 total
Exercise: $508896.00From: 2007-12-10Exp: 2009-05-15→ Common Stock (678,538 underlying)
Other
Series G Preferred Stock
2009-12-18$13.00/sh+9,665$125,645→ 9,665 total
Exercise: $13.00From: 2009-12-18→ Common Stock (966,500 underlying)
Other
Series G Preferred Stock
2009-12-18$13.00/sh+44,323$576,199→ 44,323 total
Exercise: $13.00From: 2009-12-18→ Common Stock (4,432,300 underlying)
Other
Convertible Note
2009-12-18→ 0 total
Exercise: $91104.00From: 2007-12-05Exp: 2009-05-15→ Common Stock (121,472 underlying)

Footnotes (5)

[F1]These securities are owned directly by Life Sciences Opportunities Fund II, L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II, L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial owernship of the reported securities except to the extent of their pecuniary interest therein.
[F2]These securities are owned directly by Life Sciences Opportunities Fund II (Institutional), L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II (Institutional), L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial owernship of the reported securities except to the extent of their pecuniary interest therein.
[F3]Series G Convertible Preferred Stock was issued pursuant to the terms of a Purchase Agreement dated as of December 18, 2009. The Shares are convertible at any time by the purchasers into Commn Stock at the rate 100 shares of Common Stock per each shares of Series G Preferred Stock or $0.13 per share. LOF and LOFI paid for the Series G Preferred by the cancellation of the $600,000 outstanding principal amount of and $101,834.06 accrued interest through December 18, 2009 on the 2007 Convertible Subordinated Promissory Notes dated as of December 5, 2007
[F4]Convertible Notes and Warrants were issued pursuant to the terms of a Convertible Note Purchase and Warrant Agreement dated as of December 5, 2007. The Notes are convertible at any time by the purchasers into Commn Stock at the rate of $0.75 per share. The warrants have an exercise price of $0.75 per share. A purchaser received a warrant to purchase 0.13333 shares of common stock for every $1.00 loaned to the issuer.
[F5]None

Documents

1 file

4
rrd368935.xmlPrimary

Issuer

BIOJECT MEDICAL TECHNOLOGIES INC

CIK 0000810084

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001280952

Filing Metadata

Form type: 4
Filed: Feb 4, 7:00 PM ET
Accepted: Feb 5, 4:57 PM ET
Size: 19.4 KB

View on SEC.gov